Answers are grounded in this paper and cite their sources.
Persons with end stage kidney disease receiving haemodialysis are at high risk for severe COVID-19 disease [1]. Due to possible immune dysfunction, advanced age, and high prevalence of additional underlying conditions, including immunocompromising conditions, among individuals on hemodialysis, reduced vaccine effectiveness is a concern [2] and this holds true for infections with the SARS-CoV-2 omicron variant [3]. Whilst cohort studies suggest that updated COVID-19 vaccines from 2023/2024 provided protection against COVID-19-associated hospitalization, death, and thromboembolic events among patients receiving hemodialysis [4], preliminary data about the immune response to JN.1 mRNA vaccines in dialysis patients are lacking.
No takes yet. Share an insight, caveat, or question.
Stankov et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: